Annual report
2796.TEDINET S100YXWI
Period2025-06-01 → 2026-05-31
Filed2026-08-20
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 156
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥69.5bn | 2025-06-01 → 2026-05-31 | Cons. | Net sales |
| Revenue | ¥63.5bn | 2024-06-01 → 2025-05-31 | Cons. | Net sales |
| Revenue | ¥54.5bn | 2023-06-01 → 2024-05-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥52.0bn | 2022-06-01 → 2023-05-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥51.6bn | 2021-06-01 → 2022-05-31v | Cons. | Net sales (5-year summary) |
| Operating income | ¥979m | 2025-06-01 → 2026-05-31 | Cons. | Operating income |
| Operating income | ¥293m | 2024-06-01 → 2025-05-31 | Cons. | Operating income |
| Ordinary income | ¥715m | 2025-06-01 → 2026-05-31 | Cons. | Ordinary income |
| Ordinary income | ¥136m | 2024-06-01 → 2025-05-31 | Cons. | Ordinary income |
| Ordinary income | ¥833m | 2023-06-01 → 2024-05-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.4bn | 2022-06-01 → 2023-05-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.5bn | 2021-06-01 → 2022-05-31v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥698m | 2025-06-01 → 2026-05-31 | Cons. | Income before income taxes |
| Profit before tax | ¥8m | 2024-06-01 → 2025-05-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥114m | 2025-06-01 → 2026-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥367m | 2024-06-01 → 2025-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥351m | 2023-06-01 → 2024-05-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥333m | 2022-06-01 → 2023-05-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥447m | 2021-06-01 → 2022-05-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥107m | 2025-06-01 → 2026-05-31 | Cons. | Profit loss |
| Net income | −¥381m | 2024-06-01 → 2025-05-31 | Cons. | Profit loss |
| Total assets | ¥32.7bn | at 2026-05-31 | Cons. | Assets |
| Total assets | ¥31.9bn | at 2025-05-31 | Cons. | Assets |
| Total assets | ¥29.5bn | at 2024-05-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥23.4bn | at 2023-05-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥23.7bn | at 2022-05-31v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥25.8bn | at 2026-05-31 | Cons. | Liabilities |
| Total liabilities | ¥25.0bn | at 2025-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥6.9bn | at 2026-05-31 | Cons. | Net assets |
| Net assets / equity | ¥6.9bn | at 2025-05-31 | Cons. | Net assets |
| Net assets / equity | ¥7.4bn | at 2024-05-31v | Cons. | Net assets |
| Net assets / equity | ¥7.0bn | at 2023-05-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥6.7bn | at 2022-05-31v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥6.0bn | at 2026-05-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.9bn | at 2025-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥6.0bn | at 2026-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.9bn | at 2025-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.1bn | at 2024-05-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.7bn | at 2023-05-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥4.0bn | at 2022-05-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥3.3bn | 2025-06-01 → 2026-05-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.3bn | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.7bn | 2023-06-01 → 2024-05-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.5bn | 2022-06-01 → 2023-05-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥713m | 2021-06-01 → 2022-05-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥2.0bn | 2025-06-01 → 2026-05-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥4.5bn | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥3.1bn | 2023-06-01 → 2024-05-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥703m | 2022-06-01 → 2023-05-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥292m | 2021-06-01 → 2022-05-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥181m | 2025-06-01 → 2026-05-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥939m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥2.8bn | 2023-06-01 → 2024-05-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.1bn | 2022-06-01 → 2023-05-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.0bn | 2021-06-01 → 2022-05-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥10.01 | 2025-06-01 → 2026-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-32.48 | 2024-06-01 → 2025-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-33.41 | 2023-06-01 → 2024-05-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥35.45 | 2022-06-01 → 2023-05-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥47.99 | 2021-06-01 → 2022-05-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥9.62 | 2025-06-01 → 2026-05-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥26.89 | 2022-06-01 → 2023-05-31v | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥36.29 | 2021-06-01 → 2022-05-31v | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥576.71 | at 2026-05-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥586.21 | at 2025-05-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥636.25 | at 2024-05-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥708.01 | at 2023-05-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥684.2 | at 2022-05-31v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 20.3% | at 2026-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 20.9% | at 2025-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 24.3% | at 2024-05-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.5% | at 2023-05-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 26.9% | at 2022-05-31v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 1.7% | 2025-06-01 → 2026-05-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | -5.3% | 2024-06-01 → 2025-05-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | -5.1% | 2023-06-01 → 2024-05-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.1% | 2022-06-01 → 2023-05-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.2% | 2021-06-01 → 2022-05-31v | Cons. | Rate of return on equity (5-year summary) |
| Employees | 2,031 | at 2026-05-31 | Cons. | Number of employees |
| Employees | 2,039 | at 2025-05-31 | Cons. | Number of employees |
| Employees | 1,848 | at 2024-05-31v | Cons. | Number of employees |
| Employees | 1,555 | at 2023-05-31v | Cons. | Number of employees |
| Employees | 1,544 | at 2022-05-31v | Cons. | Number of employees |
| Revenue | ¥2.2bn | 2025-06-01 → 2026-05-31 | Standalone | Operating revenue1 |
| Revenue | ¥1.9bn | 2024-06-01 → 2025-05-31 | Standalone | Operating revenue1 |
| Revenue | ¥2.2bn | 2023-06-01 → 2024-05-31v | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥1.3bn | 2022-06-01 → 2023-05-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.3bn | 2021-06-01 → 2022-05-31v | Standalone | Net sales (5-year summary) |
| Operating income | ¥1.1bn | 2025-06-01 → 2026-05-31 | Standalone | Operating income |
| Operating income | ¥659m | 2024-06-01 → 2025-05-31 | Standalone | Operating income |
| Ordinary income | ¥787m | 2025-06-01 → 2026-05-31 | Standalone | Ordinary income |
| Ordinary income | ¥481m | 2024-06-01 → 2025-05-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.1bn | 2023-06-01 → 2024-05-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥415m | 2022-06-01 → 2023-05-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥406m | 2021-06-01 → 2022-05-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥195m | 2025-06-01 → 2026-05-31 | Standalone | Income before income taxes |
| Profit before tax | ¥204m | 2024-06-01 → 2025-05-31 | Standalone | Income before income taxes |
| Net income | ¥157m | 2025-06-01 → 2026-05-31 | Standalone | Profit loss |
| Net income | ¥195m | 2024-06-01 → 2025-05-31 | Standalone | Profit loss |
| Net income | ¥1.0bn | 2023-06-01 → 2024-05-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥82m | 2022-06-01 → 2023-05-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥122m | 2021-06-01 → 2022-05-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥25.4bn | at 2026-05-31 | Standalone | Assets |
| Total assets | ¥25.6bn | at 2025-05-31 | Standalone | Assets |
| Total assets | ¥19.4bn | at 2024-05-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥14.1bn | at 2023-05-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥14.6bn | at 2022-05-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥18.6bn | at 2026-05-31 | Standalone | Liabilities |
| Total liabilities | ¥18.9bn | at 2025-05-31 | Standalone | Liabilities |
| Net assets / equity | ¥6.8bn | at 2026-05-31 | Standalone | Net assets |
| Net assets / equity | ¥6.7bn | at 2025-05-31 | Standalone | Net assets |
| Net assets / equity | ¥6.7bn | at 2024-05-31v | Standalone | Net assets |
| Net assets / equity | ¥4.8bn | at 2023-05-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥4.8bn | at 2022-05-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥4.5bn | at 2026-05-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥4.4bn | at 2025-05-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥13.72 | 2025-06-01 → 2026-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥17.28 | 2024-06-01 → 2025-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥98.47 | 2023-06-01 → 2024-05-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥8.77 | 2022-06-01 → 2023-05-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥13.11 | 2021-06-01 → 2022-05-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥13.19 | 2025-06-01 → 2026-05-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥16.59 | 2024-06-01 → 2025-05-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥94.3 | 2023-06-01 → 2024-05-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥6.78 | 2022-06-01 → 2023-05-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥10.03 | 2021-06-01 → 2022-05-31v | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥14 | 2025-06-01 → 2026-05-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥14 | 2024-06-01 → 2025-05-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥20 | 2023-06-01 → 2024-05-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥14 | 2022-06-01 → 2023-05-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥14 | 2021-06-01 → 2022-05-31v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥574.03 | at 2026-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥575.03 | at 2025-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥577.28 | at 2024-05-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥488.13 | at 2023-05-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥492.05 | at 2022-05-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 26.0% | at 2026-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 25.5% | at 2025-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.5% | at 2024-05-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.7% | at 2023-05-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.6% | at 2022-05-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 2.4% | 2025-06-01 → 2026-05-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.0% | 2024-06-01 → 2025-05-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 18.7% | 2023-06-01 → 2024-05-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.8% | 2022-06-01 → 2023-05-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.7% | 2021-06-01 → 2022-05-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 12,060,381 | at 2026-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 12,060,381 | at 2025-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 12,060,381 | at 2024-05-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 9,746,645 | at 2023-05-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 9,673,785 | at 2022-05-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 71 | at 2026-05-31 | Standalone | Number of employees |
| Employees | 66 | at 2025-05-31 | Standalone | Number of employees |
| Employees | 64 | at 2024-05-31v | Standalone | Number of employees |
| Employees | 64 | at 2023-05-31v | Standalone | Number of employees |
| Employees | 60 | at 2022-05-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 93
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2025-06-01 → 2026-05-31 | ¥377m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2025-06-01 → 2026-05-31 | ¥125m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2026-05-31 | 83 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-06-01 → 2026-05-31 | ¥986m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-06-01 → 2026-05-31 | ¥986m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2026-05-31 | ¥3.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-06-01 → 2026-05-31 | −¥113m |
| Reconciling Itemsreconciling | segment assets | at 2026-05-31 | ¥45m |
| Reconciling Itemsreconciling | segment profit | 2025-06-01 → 2026-05-31 | −¥397m |
| Cosmetic Drug And Convenience Storereportable segment | capex | 2025-06-01 → 2026-05-31 | ¥0 |
| Cosmetic Drug And Convenience Storereportable segment | depreciation | 2025-06-01 → 2026-05-31 | ¥27m |
| Cosmetic Drug And Convenience Storereportable segment | employees | at 2026-05-31 | 139 pure |
| Cosmetic Drug And Convenience Storereportable segment | revenue | 2025-06-01 → 2026-05-31 | ¥8.0bn |
| Cosmetic Drug And Convenience Storereportable segment | revenue external | 2025-06-01 → 2026-05-31 | ¥8.0bn |
| Cosmetic Drug And Convenience Storereportable segment | segment assets | at 2026-05-31 | ¥1.9bn |
| Cosmetic Drug And Convenience Storereportable segment | segment profit | 2025-06-01 → 2026-05-31 | −¥83m |
| Custody Of Medical Documentsreportable segment | capex | 2025-06-01 → 2026-05-31 | ¥22m |
| Custody Of Medical Documentsreportable segment | depreciation | 2025-06-01 → 2026-05-31 | ¥38m |
| Custody Of Medical Documentsreportable segment | employees | at 2026-05-31 | 30 pure |
| Custody Of Medical Documentsreportable segment | revenue | 2025-06-01 → 2026-05-31 | ¥647m |
| Custody Of Medical Documentsreportable segment | revenue external | 2025-06-01 → 2026-05-31 | ¥647m |
| Custody Of Medical Documentsreportable segment | segment assets | at 2026-05-31 | ¥2.4bn |
| Custody Of Medical Documentsreportable segment | segment profit | 2025-06-01 → 2026-05-31 | ¥100m |
| Dispensing Pharmacyreportable segment | capex | 2025-06-01 → 2026-05-31 | ¥864m |
| Dispensing Pharmacyreportable segment | depreciation | 2025-06-01 → 2026-05-31 | ¥565m |
| Dispensing Pharmacyreportable segment | employees | at 2026-05-31 | 1658 pure |
| Dispensing Pharmacyreportable segment | revenue | 2025-06-01 → 2026-05-31 | ¥59.3bn |
| Dispensing Pharmacyreportable segment | revenue external | 2025-06-01 → 2026-05-31 | ¥59.3bn |
| Dispensing Pharmacyreportable segment | segment assets | at 2026-05-31 | ¥24.6bn |
| Dispensing Pharmacyreportable segment | segment profit | 2025-06-01 → 2026-05-31 | ¥1.4bn |
| Medical Mallreportable segment | capex | 2025-06-01 → 2026-05-31 | ¥24m |
| Medical Mallreportable segment | depreciation | 2025-06-01 → 2026-05-31 | ¥32m |
| Medical Mallreportable segment | employees | at 2026-05-31 | 18 pure |
| Medical Mallreportable segment | revenue | 2025-06-01 → 2026-05-31 | ¥505m |
| Medical Mallreportable segment | revenue external | 2025-06-01 → 2026-05-31 | ¥505m |
| Medical Mallreportable segment | segment assets | at 2026-05-31 | ¥266m |
| Medical Mallreportable segment | segment profit | 2025-06-01 → 2026-05-31 | ¥87m |
| —segment total | capex | 2025-06-01 → 2026-05-31 | ¥912m |
| —segment total | depreciation | 2025-06-01 → 2026-05-31 | ¥663m |
| —segment total | revenue | 2025-06-01 → 2026-05-31 | ¥68.5bn |
| —segment total | revenue external | 2025-06-01 → 2026-05-31 | ¥68.5bn |
| —segment total | segment assets | at 2026-05-31 | ¥29.3bn |
| —segment total | segment profit | 2025-06-01 → 2026-05-31 | ¥1.5bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2025-06-01 → 2026-05-31 | ¥1.3bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2025-06-01 → 2026-05-31 | ¥789m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-06-01 → 2026-05-31 | ¥69.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-06-01 → 2026-05-31 | ¥69.5bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2026-05-31 | ¥32.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-06-01 → 2026-05-31 | ¥1.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2024-06-01 → 2025-05-31 | ¥153m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2024-06-01 → 2025-05-31 | ¥92m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-06-01 → 2025-05-31 | ¥1.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-06-01 → 2025-05-31 | ¥1.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2025-05-31 | ¥1.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-06-01 → 2025-05-31 | −¥52m |
| Reconciling Itemsreconciling | segment assets | at 2025-05-31 | ¥45m |
| Reconciling Itemsreconciling | segment profit | 2024-06-01 → 2025-05-31 | −¥342m |
| Cosmetic Drug And Convenience Storereportable segment | capex | 2024-06-01 → 2025-05-31 | ¥11m |
| Cosmetic Drug And Convenience Storereportable segment | depreciation | 2024-06-01 → 2025-05-31 | ¥27m |
| Cosmetic Drug And Convenience Storereportable segment | revenue | 2024-06-01 → 2025-05-31 | ¥8.7bn |
| Cosmetic Drug And Convenience Storereportable segment | revenue external | 2024-06-01 → 2025-05-31 | ¥8.7bn |
| Cosmetic Drug And Convenience Storereportable segment | segment assets | at 2025-05-31 | ¥2.0bn |
| Cosmetic Drug And Convenience Storereportable segment | segment profit | 2024-06-01 → 2025-05-31 | −¥44m |
| Custody Of Medical Documentsreportable segment | capex | 2024-06-01 → 2025-05-31 | ¥37m |
| Custody Of Medical Documentsreportable segment | depreciation | 2024-06-01 → 2025-05-31 | ¥42m |
| Custody Of Medical Documentsreportable segment | revenue | 2024-06-01 → 2025-05-31 | ¥609m |
| Custody Of Medical Documentsreportable segment | revenue external | 2024-06-01 → 2025-05-31 | ¥609m |
| Custody Of Medical Documentsreportable segment | segment assets | at 2025-05-31 | ¥1.3bn |
| Custody Of Medical Documentsreportable segment | segment profit | 2024-06-01 → 2025-05-31 | ¥51m |
| Dispensing Pharmacyreportable segment | capex | 2024-06-01 → 2025-05-31 | ¥1.8bn |
| Dispensing Pharmacyreportable segment | depreciation | 2024-06-01 → 2025-05-31 | ¥549m |
| Dispensing Pharmacyreportable segment | revenue | 2024-06-01 → 2025-05-31 | ¥52.6bn |
| Dispensing Pharmacyreportable segment | revenue external | 2024-06-01 → 2025-05-31 | ¥52.6bn |
| Dispensing Pharmacyreportable segment | segment assets | at 2025-05-31 | ¥26.7bn |
| Dispensing Pharmacyreportable segment | segment profit | 2024-06-01 → 2025-05-31 | ¥578m |
| Medical Mallreportable segment | capex | 2024-06-01 → 2025-05-31 | ¥101m |
| Medical Mallreportable segment | depreciation | 2024-06-01 → 2025-05-31 | ¥17m |
| Medical Mallreportable segment | revenue | 2024-06-01 → 2025-05-31 | ¥511m |
| Medical Mallreportable segment | revenue external | 2024-06-01 → 2025-05-31 | ¥511m |
| Medical Mallreportable segment | segment assets | at 2025-05-31 | ¥299m |
| Medical Mallreportable segment | segment profit | 2024-06-01 → 2025-05-31 | ¥103m |
| —segment total | capex | 2024-06-01 → 2025-05-31 | ¥1.9bn |
| —segment total | depreciation | 2024-06-01 → 2025-05-31 | ¥637m |
| —segment total | revenue | 2024-06-01 → 2025-05-31 | ¥62.4bn |
| —segment total | revenue external | 2024-06-01 → 2025-05-31 | ¥62.4bn |
| —segment total | segment assets | at 2025-05-31 | ¥30.2bn |
| —segment total | segment profit | 2024-06-01 → 2025-05-31 | ¥688m |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-06-01 → 2025-05-31 | ¥2.1bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-06-01 → 2025-05-31 | ¥730m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-06-01 → 2025-05-31 | ¥63.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-06-01 → 2025-05-31 | ¥63.5bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-05-31 | ¥31.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-06-01 → 2025-05-31 | ¥636m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,641
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of employees | Prior1YearInstant_NonConsolidatedMember | 66 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 71 | |
| Average number of temporary workers | Prior4YearInstant_NonConsolidatedMember | 5 | |
| Average number of temporary workers | Prior3YearInstant_NonConsolidatedMember | 4 | |
| Average number of temporary workers | Prior2YearInstant_NonConsolidatedMember | 6 | |
| Average number of temporary workers | Prior1YearInstant_NonConsolidatedMember | 6 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 17 | |
| Total shareholder return | Prior4YearInstant_NonConsolidatedMember | 0.957 | |
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | 0.825 | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 0.894 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 0.706 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 0.751 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | 1.018 | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 1.166 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 1.552 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 1.608 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 2.324 | |
| Gross scope1 greenhouse gas emissions scope1 and2 greenhouse gas emissions | CurrentYearDuration_ConsolidatedAccountingGroupMember | 357 | |
| Gross scope2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | CurrentYearDuration_ConsolidatedAccountingGroupMember | 5567 | |
| Gross scope1 and2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | CurrentYearDuration_ConsolidatedAccountingGroupMember | 5924 | |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E05379-000DispensingPharmacyReportableSegmentsMember | 10000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 777000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E05379-000DispensingPharmacyReportableSegmentsMember | 722000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E05379-000CosmeticDrugAndConvenienceStoreReportableSegmentsMember | 0 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E05379-000CustodyOfMedicalDocumentsReportableSegmentsMember | 15000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E05379-000MedicalMallReportableSegmentsMember | 16000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_OtherReportableSegmentsMember | 23000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 12060381 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 12060381 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 12060381 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 12060381 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | 0 | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 1 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 14 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 7 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 51 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 19936 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 20109 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | 0 | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 1000 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 107 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 63675 | |
| Number of shares held number of units foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 21 | |
| Number of shares held number of units foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 41 | |
| Number of shares held number of units individuals and others | CurrentYearInstant_OrdinaryShareMember | 55661 | |
| Number of shares held number of units total | CurrentYearInstant_OrdinaryShareMember | 120505 | |
| Number of shares held shares less than one unit | CurrentYearInstant_OrdinaryShareMember | 9881 | |
| Percentage of shareholdings national and local governments | CurrentYearInstant_OrdinaryShareMember | 0.00 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |